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ABSTRACT 
 
Cationic peptides proved fundamental importance as pharmaceutical agents and/or drug-carrier 
moieties functioning in cellular processes. The comparison of the in vitro activity of these 
peptides is an experimental challenge and a combination of different methods, such as 
cytotoxicity, internalisation rate, haemolytic and antibacterial effect, is necessary. At the same 
time several issues need to be addressed as the assay conditions have a great influence on the 
measured biological effects and the experimental setup need to be optimised. Therefore, critical 
comparison of results from different assays using representative examples of cell penetrating 
and antimicrobial peptides was performed and optimal test conditions were suggested. Our 
main goal was to identify carrier peptides for drug delivery systems of antimicrobial drug 
candidates. Based on the results of internalisation, haemolytic, cytotoxic and antibacterial 
activity assays, a classification of cationic peptides is advocated. We found eight promising 
carrier peptides with good penetration ability of which Penetratin, Tat, Buforin and Dhvar4 
peptides showed low adverse haemolytic effect. Penetratin, Transportan, Dhvar4 and the hybrid 
CM15 peptide had the most potent antibacterial activity on Streptococcus pneumoniae (MIC 
lower than 1.2 M) and Transportan was effective against Mycobacterium tuberculosis as well. 
The most selective peptide was the Penetratin, where the effective antimicrobial concentration 
on pneumococcus was more than 250-times lower than the HC50 value. Therefore, these 
peptides and their analogues will be further investigated as drug delivery systems for 
antimicrobial agents. 
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1. INTRODUCTION 
 
In the design and development of new antimicrobial drug candidates, delivery to target site is 
one of the major consideration. However, several libraries of synthetic compounds providing 
activity against a vast spectrum of pathogens have been discovered so far, the general inability 
to penetrate the target cells seems to be the main obstacles, especially in the case of diseases 
that are caused by intracellular bacteria (Brown and Wright 2016). 
 
The cellular uptake rate and the bioavailability of drug compounds can be enhanced by covalent 
attachment to appropriate targeting or carrier peptides. Cationic oligopeptides, including cell 
penetrating peptides (CPP) and certain antimicrobial peptides (AMP) have the ability to cross 
the lipid membrane and to access intracellular targets. Several cationic oligopeptides entered 
clinical trials (Marr et al. 2006; Yeung et al. 2011). However, lack of cell specificity and 
extensive cytotoxicity of CPPs still need to be addressed. To improve the therapeutic effect of 
these peptides, intracellular trafficking and antimicrobial activity with low cytotoxicity toward 
human host cells is needed. For the calculation of the in vitro selectivity the haemolytic activity 
toward human red blood cells (RBC) is often used for the comparison to the antimicrobial 
activity (Chen et al. 2005). 
 
1.1. Experimental Conditions of In Vitro Assays  
To determine the in vitro selectivity of membrane active cationic peptides many types of 
biological assays are described in the literature. Previous studies have warned that the absence 
of haemolysis or high HC50 values in certain media (i.e. PBS) can give untrue results, when the 
selectivity index is calculated (Saberwal and Nagaraj 1994). Even in the case of the bee venom 
Melittin, haemolytic activity can be inhibited if the phosphate concentration is raised 
(Helmerhorst et al. 1999; Portlock et al. 1990). In general, the membrane activity of many 
cationic peptides is strongly dependent on the ionic strength and salt content of the used media 
(Helmerhorst et al. 1999; Herbel and Wink 2016). Raghuraman and colleagues studied the effect 
of ionic strength on the dynamics and aggregation behaviour of Melittin and they showed, that the 
peptide undergoes a structural transition from a random coil monomer to an α-helical tetramer at high 
ionic strength (Raghuraman and Chattopadhyay 2006; Raghuraman et al. 2006).  
 
The most significant differences in the test conditions can be found in the haemolytic assays of 
peptides. Important variants are as follows:  (i) concentration of RBC (0.5% v/v (Hollmann et 
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al. 2016), 1% (Kobayashi et al. 2000), 2% (Yang et al. 2013), 4% (Lee and Lee 2008; Song et 
al. 2005), 20% (Chongsiriwatana et al. 2008), 2 × 106 cells/mL (Li et al. 2005) or 2.5 × 108 
cells/mL (Dathe et al. 2001; Dathe et al. 1996), 1.2 × 109 cells/mL (Zeitler et al. 2013) etc.); (ii) 
incubation media (PBS (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; Hollmann 
et al. 2016; Lee and Lee 2008; Song et al. 2005), Tris (Dathe et al. 2001; Dathe et al. 1996; 
Zeitler et al. 2013), RPMI-1640 or HEPES buffer (Li et al. 2005), 0.9% NaCl or normal saline 
(Wu et al. 2014), etc.); (iii) incubation time (30 min (Hollmann et al. 2016; Wu et al. 2014), 1 
hour (Chongsiriwatana et al. 2008; Dennison and Phoenix 2014; Yang et al. 2013), 4 hrs (Li et 
al. 2005) or 18-24 hrs (Mojsoska et al. 2015)); (iii) used positive control (0.1% Triton-X 
(Dennison and Phoenix 2014; Lee and Lee 2008; Song et al. 2005), 1% Triton-X (Mojsoska et 
al. 2015), 10% Triton-X (Wu et al. 2014), distilled water (Hollmann et al. 2016; Yang et al. 
2013), 2 % SDS (Zeitler et al. 2013), 0.05% saponin (Davanco et al. 2014). There are 
differences even in the used wavelength at which the optical density of released haemoglobin 
is determined (λ=350 nm (Chongsiriwatana et al. 2008), 405-415 nm (Kaushik et al. 2012; Lee 
and Lee 2008; Song et al. 2005; Zeitler et al. 2013) , 540-550 nm (Davanco et al. 2014; 
Hollmann et al. 2016; Mojsoska et al. 2015; Yang et al. 2013) or 570 nm (Dennison and Phoenix 
2014; Wu et al. 2014)). 
 
Because of the different test conditions, it is questionable whether the results of the haemolytic 
assays can be properly compared to the antimicrobial activity and/or cytotoxicity that are 
usually performed in lower ionic strength media or broths (RPMI, HEPES, DMEM, Bouillon, 
etc.). Therefore we have investigated in the comparative analysis of haemolytic activity, 
cytotoxicity, cellular uptake and antimicrobial activity of cationic oligopeptides with the aim to 
clarify the role of experimental conditions such as the cell type, concentration of cells, used 
media, incubation time, anticoagulant and counter-ion, etc.  
 
1.2. Peptide Selection 
In this project, well studied cationic oligopeptides which can be considered as representative 
CPPs and AMPs, were chosen for critical analysis. Our goal was to identify peptides as 
promising antibacterial drug carriers with potent penetrating ability, antibacterial effect and 
suitable selectivity. Criteria of the peptide selection were the following: size (lower than 25 
amino acids); cationic character; synthetic considerations, such as bearing suitable conjugation 
site; literature data on membrane activity (e.g. cell penetration and/or antibacterial effect). 
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In many cases, however, the exact mechanism of bacterial killing of AMPs is not known; these 
evolutionarily conserved peptides can permeabilise the phospholipid membrane and provoke a 
broad spectrum of antimicrobial activity against bacteria, viruses, and fungi (Reddy et al. 2004; 
Yeaman and Yount 2003). Many antimicrobial peptides were isolated from amphibians, such 
as Magainin (Zasloff 1987) and Buforin (Park et al. 1996). Granulysin, a 9 kDa protein found 
in granules of cytotoxic T lymphocytes and natural killer cells, lyses a variety of tumour and 
bacterial cells in vitro, and directly kill Mycobacterium tuberculosis (Stenger et al. 1998). 
GranF2, a 23-mer peptide synthetic derivative, represents a helix-loop-helix region, which is 
postulated to be the membrane-docking part of Granulysin protein (Andreu et al. 1999). 
Histatins are salivary histidine-rich cationic peptides found in human parotid secretion. 
Synthetic derivatives, including Dhvar4, were studied on the ability to adopt helical 
conformation which is considered to be the key feature to act as membrane-active antimicrobial 
peptides (Helmerhorst et al. 1997). Crot(1-9,38-42) peptide is representing the N- and C-
terminus of Crotamine, a toxin found in the venom of rattlesnake (Andreu et al. 1992). Recently, 
chimera peptides were developed to improve the biological activity: CM15 is a linear, hybrid 
AMP composed of Cecropin A (1-7) and Melittin (2-9) (Radis-Baptista et al. 2008). The major 
toxin found in bee venom is Melittin, a linear 26-residue peptide, which displays strong lytic 
activity against bacteria and human cells (Habermann 1972), and it is often used as a positive 
control in haemolytic assays. 
 
Cell penetrating peptides could have a great pharmaceutical potential as in vitro and in vivo 
delivery vectors for a wide range of bioactive cargos. CPPs are of different sizes, amino acid 
sequences, and charges but all published CPPs have the ability to translocate the plasma 
membrane and facilitate the delivery to the cytoplasm (El-Andaloussi et al. 2005; Hudecz et al. 
2005; Morris et al. 2008; Vives et al. 2008). During the last two decades several CPPs were 
described. Tat (transactivator of transcription) and Penetratin, the two most studied CPPs, were 
derived from the sequence of HIV transactivator protein (Green and Loewenstein 1988) and the 
third helix of the homeodomain of Drosophila Antennapedia protein (Derossi et al. 1994). 
Transportan is a hybrid peptide, constructed from a 6-residue sequence of the neuropeptide 
Galanin (GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS) with a peptide toxin from wasp 
venom (mastoparan, INLKALAALAKKIL) connected via a lysine (Langel et al. 1996).  
 
Tuftsin is a receptor binding peptide produced by the enzymatic cleavage of the Fc-domain of 
the heavy chain of immunoglobulin G. Based on the canine tuftsin sequence, [TKPKG]4 (OT20) 
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peptide was developed in our laboratory (Bai et al. 2008; Horvati et al. 2012; Mezo et al. 2004). 
OT20 peptide, a tetramer derivative of tuftsin, represents comparable chain length (20-mer), 
net charge (9+) and hydrophilicity therefore it was used as negative control in this study.  
 
2. MATERIALS AND METHODS 
 
Materials 
N,N’-diisopropylcarbodiimide (DIC), triisopropylsilane (TIS) and Amberlit IRA-400 anion-
exchange resin were purchased from Fluka. The amino acid derivatives were obtained from 
Reanal or from IRIS Biotech. 1-hydroxybenzotriazole (HOBt) and trifluoroacetic acid (TFA) 
was also from IRIS Biotech. Fmoc-Rink Amide MBHA resin was purchased from 
NovaBiochem. Acetonitrile and dimethyl sulfoxide (DMSO) were from Merck. N,N-
dimethylformamide (DMF) and dichloromethane (DCM) were from Reanal. 
Chromatographically purified bovine serum albumin (BSA), 5(6)-carboxyfluorescein (Cf) and 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were obtained from Sigma-Aldrich. 
 
For the in vitro assays RPMI-1640 medium, Dulbecco's Modified Eagle's Medium (DMEM), 
fetal calf serum (FCS), nonessential amino acids, 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT), sodium dodecyl sulfate (SDS), Löwenstein-Jensen medium base 
were obtained from Sigma-Aldrich. Sula medium, PBS buffer (10 mM sodium phosphate in 
150 mM NaCl, pH 7.4), Tris buffer (0.1 M tris(hydroxymethyl)aminomethane, pH 7.4, adjusted 
with HCl), and HPMI buffer (9 mM glucose, 10 mM NaHCO3, 119 mM NaCl, 9 mM HEPES, 
5 mM KCl, 0.85 mM MgCl2, 0.053 mM CaCl2, 5 mM Na2HPO4 × 2H2O, pH 7.4) were prepared 
in our laboratory using components obtained from Sigma-Aldrich. 0.9% NaCl was a Fresenius 
infusion solution. 
 
2.1. Peptide Synthesis and Purification 
Peptides were produced on 100 mg Fmoc-Rink Amide MBHA (capacity = 0.67 mmol/g) resin 
in an automated peptide synthesizer (Syro-I, Biotage) using standard Fmoc/tBu strategy with 
DIC/HOBt coupling reagents. Peptides were cleaved from the resin with TFA/H2O/TIS (9.5 : 
2.5 : 2.5 v/v) mixture (2 hrs, RT). After filtration the compounds were precipitated in cold 
diethyl ether, centrifuged (4000 rpm, 5 min) and freeze-dried from water. Crude products were 
purified by RP-HPLC on a semipreparative C-18 Phenomenex Jupiter column (250×10 mm) 
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using gradient elution, consisted of 0.1% TFA in water (eluent A) and 0.1% TFA in 
acetonitrile/water = 80/20 (v/v) (eluent B).  
 
For the cellular uptake studies N-terminus of the peptides were labelled with 5(6)-
carboxyfluorescein (Cf) using DIC/HOBt coupling method. Cleavage, work-up and purification 
of Cf-peptides were performed in the same way as mentioned above.  
 
2.2. Peptide Characterization 
Purified peptides were analysed by RP-HPLC on an analytical C-18 Eurospher-100 (5 µm, 
250×4 mm) column using gradient elution with the above mentioned eluent A and B (flow rate 
was 1 mL/min, UV detection at λ=220 nm).  
 
Molecular mass of peptides was determined by using a Bruker Esquire 3000+ ESI mass 
spectrometer.  Peptide samples were dissolved in a mixture of acetonitrile/water = 1/1 (v/v) 
containing 0.1% acetic acid and introduced by a syringe pump with a flow rate of 10 L/min. 
 
2.2.1. Determination of Peptide Content by Amino Acid Analysis  
The peptide content was determined by amino acid analysis using a Sykam Amino Acid S433H 
analyser equipped with an ion-exchange separation column and postcolumn derivatization. 
Prior to analysis, samples were hydrolysed with 6 M HCl in sealed and evacuated tubes at 
110°C for 24 h. For post-column derivatization the ninhydrin-method was used. 
 
2.2.2. Counter-ion Replacement and the Determination of Fluorine Content 
Acetate-exchange of the purified peptides was performed using Amberlit IRA-400 (20-50 
mesh, Cl- form) anion-exchange resin. First the resin was washed with water, three times with 
0.2 M NaOH, washed with water, and treated with 20 v/v% acetic acid. After washing with 
water, 2 g resin was mixed with the peptide solution (26.5 mg / 4 ml of water). The peptide-
resin suspension was stirred for 1 h, then filtered and washed with 20 v/v% acetic acid and 
water. After freeze-drying, peptides were analysed by analytical RP-HPLC, ESI MS and amino 
acid analysis. To calculate the anion-exchange rate, the Fluorine content of the peptides was 
determined by using modified Schöniger method (Rogers and Yasuda 1959). The exchange rate 
was calculated by dividing the percentage of the Fluorine content of acetate-exchanged peptide 
by the percentage of the Fluorine content of the original peptide.  
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2.2.3. Circular dichroism (CD) spectroscopic measurements and secondary structure 
estimation 
 
Peptide samples were dissolved in deionized water and in 10 mM, pH 7.3 potassium phosphate 
buffer (0.05 M Na2SO4). Far-UV CD curves were acquired on a JASCO J-715 
spectropolarimeter at 25  0.2 C in a 0.1 cm path-length rectangular quartz cuvette (Hellma, 
USA). Temperature control was provided by a Peltier thermostat. The CD data were monitored 
in continuous scanning mode between 185 and 260 nm at a rate of 50 nm/min, with a step size 
of 0.1 nm, response time of 2 sec, three accumulations, 2 nm bandwidth. The CD curves were 
corrected by spectral contribution of blank water or buffer solution. 
CD spectra were plotted in mean residue molar CD units (/ residue) calculated by the 
following equation: 
 = / (32982cl) 
where  is the measured ellipticity as a function of wavelength (nm), c is the molar 
concentration of the peptide, and l is the optical path length (cm).  
 
The secondary structure content of CM15 was estimated from the CD spectra using the MS 
Excel version of the PEPFIT program developed originally by Reed and Reed (Amon et al. 
2008; Reed and Reed 1997). It calculates the percentage of secondary contents by fitting 
experimental data to reference secondary structure spectra. The best fit is deﬁned by the R2 
value, where an R2 = 1 corresponds to a perfect fit. Before secondary structure analysis, the CD 
spectra were smoothed with a convolution width of 17 using the Means-Movement method 
(JASCO Spectra Analysis software, version 1.53.00). 
 
2.3. Haemolytic Activity Assay  
Peripheral blood from healthy volunteers was collected in vacuum tubes containing heparin (Li-
heparin LH, VenoSafe) as anticoagulant. Tubes were centrifuged (1000 rpm, 5 min) and the 
pellet was washed 3 times with RPMI-1640 (culturing media without phenol red). To the pellet 
RPMI media was added to yield a final 4, 1, 0.25 or 0.0625 v/v% RBC suspension. Peptides 
were dissolved in the same media and three-fold serial dilution series were prepared (final 
concentration: 0.1 – 200 μM). RBC suspension (100 L/well) were placed into a 96-well cell 
culture plate and mixed with 100 L peptide solution. The plates were incubated for 4 hrs at 
37°C. After centrifugation (1500 rpm, 5 min), 100 L of the supernatant was transferred to a 
flat-bottom microtiter plate and absorbance was measured at 414 nm using an ELISA plate 
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reader (iEMS Reader, Labsystems). The percentage haemolysis was compared to 0.1 % Triton-
X treated RBC and the concentration of peptide at which 50% haemolysis (HC50 value) was 
determined.  
 
To study the time dependence of haemolysis, RBCs were incubated for 30 min or 4 hrs or 24 
hrs with CM15 peptide solution at 37°C using the same conditions as described above. To 
compare the effect of different anticoagulants on the haemolysis evoked by CM15 peptide, 
three types of vacuum tubes were used: heparin (Li-heparin LH, VenoSafe), EDTA (K3-EDTA, 
VenoSafe), citrate (Na3-citrate 9NC, VenoSafe). To determine the effect of the addition of 
stabilizer, BSA was added to the stock solution of the CM15 peptide at 5 mg/mL (0.5%) 
concentration. The influence of different buffers was tested using either PBS, TRIS buffers, 
Bouillon broth, DMEM, RPMI (without phenol red) media or Fresenius 0.9% NaCl infusion 
solution. Always the same media was used for washing, culturing the erythrocytes and for 
dissolving the peptide samples. 
 
2.4. Cell Culturing, Cytotoxicity Assay and Cell Morphology 
Peripheral blood mononuclear cells (PBMC) were prepared from peripheral blood of healthy 
volunteers (purchased from Hungarian National Blood Transfusion Service, HNBTS) using 
Ficoll-Hypaque density gradient centrifugation method. PBMC were cultured in complete 
medium prepared from RPMI-1640 supplemented with 10% FCS, 2 mM L-glutamine and 160 
µg/mL gentamycin at 37°C in 5% CO2 atmosphere. Twenty-four hours prior to treatment, 
PBMC cells were plated into a 96-well round bottom plate (250.000 cell/100 L complete 
medium).  
 
MonoMac6 human monocytic cell line (DSMZ no.: ACC 124) and HepG2 human 
hepatocellular liver carcinoma cell line (ATCC HB-8065) were maintained under conditions 
described above. For cytotoxicity assay, cells were distributed on a 96-well flat bottom tissue 
culture plate (5000 cell/100 L complete RPMI-1640 medium). 
SH-SY5Y human neuroblastoma cell line (ATCC CRL-2266) was cultured in DMEM medium 
containing 10% FCS, 2 mM L-glutamine, 160 µg/mL gentamycin, 1 mM pyruvate and 1% 
nonessential amino acids. SH-SY5Y cells (10.000 cell/100 L complete DMEM medium) were 
plated into a 96-well flat bottom tissue culture plate.  
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Prior to treatment, cells were washed with serum-free RPMI-1640 (PBMC, MonoMac6, 
HepG2) or DMEM (SH-SY5Y) medium. Peptides to be tested were dissolved in serum-free 
medium and added to the cells to achieve 0.15 M – 300 M final concentration. Cells were 
incubated with the peptides for 4 hrs, then the cell viability was tested using MTT assay (Liu et 
al. 1997; Mosmann 1983; Slater et al. 1963). Briefly, 45 μL MTT solutions were added to each 
well (2 mg/ml, solved in serum-free medium). Following 4 hrs of incubation, plates were 
centrifuged at 2000 rpm for 5 minutes, and the supernatant was carefully aspirated with a G30 
needle. The precipitated purple crystals were dissolved in 100 μL DMSO, and after 10 minutes 
agitation, the absorbance was determined at  = 540 nm and 620 nm using ELISA plate reader 
(iEMS Reader, Labsystems). Cytotoxicity, expressed in percentage as the function of peptide 
concentration was represented graphically and IC50 values were determined.  
 
To visualize cell morphology after peptide treatment, microscopic images of MonoMac6 cells 
were captured. MonoMac6 cells were plated in a 96-well flat bottom tissue culture plate (5000 
cell/100 L RPMI-1640 medium without phenol red), then treated with the peptides for 4 hrs 
at 1, 10 and 100 M final concentration. Microscopic images of the adherent cells were captured 
using an Olympus CKX41 microscope. 
 
2.5. Cellular Uptake Studies by Flow Cytometry  
The measurement of cell penetration of the compounds was evaluated on MonoMac6 human 
monocytic cell line by using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA) 
with 488 nm (Coherent Sapphire, 22 mW) laser. Cells were harvested in the logarithmic phase 
of growth and plated on a 24-well tissue culture plate (105 cells/1 mL medium/well) 24 hours 
prior to the experiment. Cf-labelled peptides were dissolved in serum free RPMI medium and 
added to the cells at 20, 10 and 5 µM final concentrations. Cells were incubated with compounds 
for 2 hrs (37 °C, 5% CO2 atmosphere). After centrifugation (1000 rpm, 5 min) and washing 
with RPMI medium, supernatant was removed and 100 μL 1 mM trypsin was added to the cells. 
After 5 min incubation at 37 oC 0.8 mL 10% FCS/HPMI medium was added than cells were 
washed and re-suspended in 0.5 mL HPMI. The cell viability was assessed using 10 µg/mL 
propidium iodide (PI) solution (for the gating strategy see Supporting Information FIGURE 
S1). The intracellular fluorescence intensity of the cells was measured on channel PE LP550 
(emission at λ = 550 nm) and data were analysed with FACSDiva 5.0 software. All 
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measurements were performed in triplicates.   Parallel with flow cytometry measurements 
microscopic image of the cells were captured with an Olympus CKX41 microscope. 
 
2.6. In Vitro Antibacterial Activity Assay 
In vitro antibacterial activity of the compounds was determined against Streptococcus 
pneumoniae (ATCC 49619) by serial dilution method in Bouillon medium, which was prepared 
in-house. Compounds were added to the medium as 10 μL DMSO solutions in duplicates (range 
of final concentrations was between 1.2 and 300 μM). Each tube was inoculated with 0.5 
Mcfarland bacteria and the minimal Inhibitory concentration (MIC) was determined after 
incubation at 37 oC for 24 hrs. MIC was the lowest concentration of a compound at which no 
visible growth of the bacteria occurred.  
 
Antitubercular effect of the compounds was also tested on Mycobacterium tuberculosis H37Rv 
(ATCC 27294) in Sula semisynthetic medium (prepared in-house) (Sula 1963; Sula and 
Sundaresan 1963; Vinsova et al. 2006) using previously described method (Baranyai et al. 
2015; Horvati et al. 2015). Compounds were dissolved in DMSO and added to the medium at 
ten various concentrations (c = 0.5 – 500 μM). MIC value was determined after incubation at 
37 oC for 28 days. In order to confirm the growth inhibition colony forming unit (CFU) was 
determined by subculturing from the Sula medium onto drug-free Löwensten-Jensen solid 
medium. Samples were further incubated for 28 days. Experiments were repeated at least two 
times. 
 
Selectivity indices were calculated from the concentration value where 50% of human RBCs 
were lysed (HC50) by the peptides divided by the minimal inhibitory concentration (MIC) 
determined against Streptococcus pneumoniae. Both in vitro measurements were performed in 
Bouillon broth using 24 hrs incubation time. 
 
2.7. Statistical Analysis 
In vitro tests were performed in triplicates and the results were expressed as mean ± Std. 
deviation. For the evaluation of haemolysis and cytotoxicity and for the determination of HC50 
and IC50 values of the peptides dose-response curves were plotted with non-linear regression 
analysis using GraphPad Prism 5.0 software. The effects of different experimental conditions 
(incubation time, media, percentage of RBC, anticoagulant and counter ion) were analysed by 
one-way ANOVA test by using GraphPad Prism 5.0 software. If means were significantly 
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different (P < 0.05), than ANOVA test was followed by a t-test (unpaired, two-tailed, 
confidence intervals: 95%). 
 
3. RESULTS AND DISCUSSION 
 
Representative examples of cationic oligopeptides, listed in TABLE 1, were critically analysed 
and compared in well-defined in vitro assays. Our aim was to find good future peptide 
candidates for antimicrobial drug delivery. Cytotoxicity, haemolytic and antimicrobial activity 
of membrane-active peptides is often used to estimate their therapeutic applicability 
(Helmerhorst et al. 1999; Maher and McClean 2006). In this paper, we show that the calculated 
selectivity index is strongly dependent on the conditions (i.e. culturing media) of the in vitro 
assays. Therefore, systematic studies were performed to establish proper test conditions for 
accurate comparison. All 11 peptides were then tested on PBMC and MonoMac6 cells, against 
two bacterial strains (S. pneumoniae and M. tuberculosis) and on human erythrocytes in 
different incubation media. As positive control, Melittin was used which has strong lytic 
activity against microbes and human cells. OT20 was the negative control in this study. OT20 
is a non membrane-active, receptor binding peptide, which represents comparable cationic 
character. 
 
TABLE 1. Origin and classification of cationic oligopeptides used in this study  
peptide classification origin ref. 
Tat(47-57) CPP HIV transactivator protein 
(Green and Loewenstein 
1988) 
Penetratin CPP Drosophila Antennapedia protein (Derossi et al. 1994) 
Transportan hybrid CPP 
constructed from Galanin and 
Mastoparan proteins 
(Langel et al. 1996) 
Magainin AMP peptide from Xenopus laevis skin (Zasloff 1987) 
Buforin II  
(5-21) 
AMP 
peptide from the stomach tissue of  Bufo 
bufo garagrizans 
(Park et al. 1996) 
GranF2 AMP peptide derived from Granulysin protein 
(Andreu et al. 1999; Stenger 
et al. 1998) 
Dhvar4 designed AMP human salivary Histatin derivative (Helmerhorst et al. 1997) 
Crot(1-9,38-
42) 
designed AMP 
Crotamine, a toxin of Crotalus durissus 
terrificus 
(Andreu et al. 1992) 
CM15 hybrid AMP from Cecropin A and Melittin sequences (Radis-Baptista et al. 2008) 
 14 
Melittin 
positive control 
(strong lytic 
activity) 
venom of Apis mellifera (Habermann 1972) 
OT20 
negative control 
peptide 
tetramer derivative of tuftsin sequence (Bai et al. 2008) 
 
3.1. Synthesis and Characteristics of Cationic Peptides 
Cationic peptides, listed in TABLE 2, were synthesized, purified and carefully characterized by 
analytical RP-HPLC, ESI MS and amino acid analysis.  
 
Throughout experimental design it is important to note that the peptide content of a lyophilised 
material can vary according to the sequence and the used synthetic procedures. Generally, the 
content of residual salt and water, which are the main impurities in a lyophilized peptide, can 
be up to 40-50%, especially in the case of high number of positively charged amino acids in the 
sequence. For more reliable comparison, precise determination of peptide content was 
evaluated by amino acid analysis. We found that the higher the average hydrophilicity (H) was, 
the lower peptide content was measured. The average peptide content was 50%, the lowest 
value was 41% for Tat(47-57) peptide (9+ charge in 11 amino acids), the highest was 58% for 
Magainin (4+ charge in 23 amino acids) (TABLE 2).  
 
TABLE 2. Analytical characteristics of  cationic peptides 
peptide sequence 
Z a 
 
Mav
 b
 
calcd / found 
Rt c 
(min) 
H d 
 
peptide 
content e 
% 
Tat(47-57) YGRKKRRQRRR 9+ 1558.9/1559.2 15.5 +2.0 41 
Penetratin RQIKIWFQNRRMKWKK 8+ 2245.7/2245.6 25.9 +0.5 49 
Transportan AGYLLGKINLKALAALAKKIL 5+ 2181.8/2181.9 29.1* -0.3 56 
Magainin GIGKFLHSAKKFGKAFVGEIMNS 4+ 2465.9/2466.0 33.0 -0.1 58 
Buforin II (5-21) RAGLQFPVGRVHRLLRK 6+ 2002.4/2002.5 26.8 +0.2 52 
GranF2 VCRTGRSRWRDVCRNFMRRYQSR 8+ 2988.5/2988.7 27.7 +0.6 45 
Dhvar4 KRLFKKLLFSLRKY 7+ 1839.4/1839.6 29.6 +0.3 48 
Crot(1-9,38-42) YKQCHKKGGKKGSG 6+ 1504.8/1504.9 11.3 +0.8 48 
CM15 KWKLFKKIGAVLKVL 6+ 1770.3/1770.4 32.0 -0.1 52 
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 6+ 2846.5/2846.6 39.6 -0.2 57 
OT20 TKPKGTKPKGTKPKGTKPKG 9+ 2063.5/2063.5 14.8 +1.1 49 
C-terminus of the peptides was amidated. 
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 a Z: net charge at neutral pH. Calculated by the number of (K+R)-(E+D). Positive charge at the N-terminus 
increases Z by 1 unit.  
b
 Measured average molecular mass by Bruker Esquire 3000+ ESI-MS.  
c
Analytical RP-HPLC, gradient: 5% B, 5 min; 5-60% B, 35 min. * gradient: 10% B, 5 min; 10-80% B, 35 min. 
d H: hydrophilicity is calculated from the average of hydrophilicity values of each amino acids (Hopp and Woods 
1981). 
e Peptide content was determined by amino acid analysis using freeze-dried final product.  
 
3.1.1. Counter-Ion Replacement 
After standard solid phase synthesis and purification, cationic peptides are often isolated as 
trifluoroacetate salts (Roux et al. 2008; Vemuri 2005). In the case of lysine and arginine rich 
peptide, the high amount of TFA can modify the biological and physicochemical properties (i.e. 
by modifying the conformation of the peptide, acidifying the media, and lowering the peptide 
content of the lyophilized powder). Therefore, we have changed the trifluoroacetate counter-
ion for acetate (which is less acidic, less toxic and has lower molecular mass) using Amberlit 
IRA-400 anion-exchange resin. This process also removed the excess TFA. Anion-exchange 
rate was monitored by elemental analysis. The Fluorine content of the peptide after acetate-
exchange was decreased dramatically and the calculated exchange rate was up to 80% (F% = 
13.42 (unchanged peptide); 2.88 (acetate-exchanged)). 
 
3.1.2. Circular Dichroism Spectroscopic Investigation of the Secondary Structure of 
CM15 Peptide 
Far-UV CD spectra of peptides represent the summation of signals from the optically active n-
* and -* transitions of the amide bonds (Toniolo et al. 2012). -Helical structures display a 
negative n-* CD band at ~220 nm and two, higher intensity negative-positive peaks at ~207 
and ~190 nm, respectively. This couplet is attributable to chiral exciton interaction of the 
helically arranged amide chromophores. The -sheet CD pattern consists of a negative n-* 
band near 217 nm and two -* exciton components below 200 nm. Unordered peptides and 
proteins show a strong negative peak centered in the 195-200 nm region and substantially 
weaker, positive or negative signals above 215 nm. Taking these into consideration, the CD 
curve of CM15 measured in water (pH ~ 6) is characteristic to the dominant contribution of the 
unordered or random coil structure (FIGURE 1) (Pistolesi et al. 2007). In full concordance with 
this, quantitative analysis of the CD data yielded 62% random coil and 26% β-sheet with no α-
helical content. Interestingly, a small fraction of type III β-turn (Reed and Reed 1997) was also 
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required to achieve the best fit between the experimental and calculated data (FIGURE 1). In 
relation to water, the negative CD band is red shifted above 200 nm in buffer solution together 
with the development of a prominent shoulder above 215 nm. According to the secondary 
structure estimation, these spectral changes can be associated to a β-turn  α-helix 
conformational conversion (FIGURE 1). These results suggest that the pH of the medium where 
CM15 acts, e.g., normal or acidic inflamed tissues, may provoke a slight, but significant 
modification of its secondary structure. 
 
FIGURE 1. Far-UV CD spectra of CM15 peptide. CM15 peptide (30 μM) was measured in 
deionized water (pH ~ 6, 0.05 M Na2SO4) and in 10 mM, pH 7.3 potassium phosphate buffer (0.05 
M Na2SO4), panel A. Panel B represents the results of the curve-fitting procedure made by using 
the PEPFIT analysis program (α-H: α-helix; β-S: β-sheet; r-C: random coil; β-T: type III β-turn). 
The inset shows the estimated secondary structure percentages of the peptide. 
 
3.2. Haemolytic Activity of Peptides: Effect of Experimental Conditions 
Published methods to determine haemolytic activity of cationic peptides often use different test 
conditions that can strongly influence the results. Therefore the effect of time, incubation buffer, 
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concentration of RBC, identity of anticoagulant and counter-ion on haemolytic activity of 
cationic peptides was investigated. To establish proper test conditions CM15 peptide was 
chosen because of its average characteristics (charge and size) and medium haemolytic activity. 
 
3.2.1 Incubation Time and Media 
First, the time dependence of haemolysis evoked by cationic peptides was studied. Erythrocytes 
were incubated for 30 min, 2 hrs, 4 hrs or 24 hrs with CM15 peptide. Half an hour was enough 
to reach the maximum haemolysis; no further haemoglobin release was detected (FIGURE 2 
A, B). Comparing the means of the HC50 values no significant difference was observed (P = 
0.4449). 
 
In contrast, the type of incubation media strongly influenced the haemolytic activity of CM15 
peptide. The resulted means of HC50 values showed significantly difference (P < 0.0001) in the 
one-way ANOVA test. In the measurement of haemolysis, isotonic conditions are required to 
prevent erythrocytes from spontaneous lysis. Most commonly PBS and TRIS buffers are used 
in haemolytic assays however, for antimicrobial and cytotoxic assays these are considered to 
be high salt buffers (Helmerhorst et al. 1999). RPMI, DMEM and other cell culturing media 
contain amino acids, vitamins, glucose as well as additional supplementary components to be 
optimal for cultivation of certain cell types and are formulated to have the final osmolality in 
the range of 290 to 310 mOs/kg. It was found that the haemolytic activity of CM15 peptide is 
significantly lower (P < 0.0001) in PBS (28.2 ± 1.22 μM) than in cell culturing DMEM media 
(DMEM: 6.70 ± 0.50 μM). Haemolysis in RPMI, DMEM and Bouillon broth were in the range 
of 6.70 to 15.32 μM (FIGURE 2 C, D). For other cationic peptides, same results were found 
namely lower HC50 values were measured in PBS and Tris buffers than cell culturing media 
and broths (data not shown). 
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FIGURE 2. Effect of incubation time (A, B) and media (C, D) on the haemolytic activity of 
CM15 peptide. Human erythrocytes were treated with CM15 peptide at various concentrations 
using different experimental conditions and the haemolysis was determined by reading the 
absorbance of the supernatant at =414 nm. Haemolysis of the erythrocytes reached the maximum 
after 30 min treatment and no further haemoglobin release was measured. The haemolytic activity 
of CM15 peptide is strongly dependent on the used incubation buffer: in PBS significantly lower 
HC50 value was measured than in low ionic strength media or broth. (One-way ANOVA test, means 
are significantly different, P < 0.0001). 
 
In published methods there are differences even in the used wavelength at which the absorbance 
of the supernatant is measured. Percentage of haemolysis is calculated by dividing the 
absorbance measured for the peptide by the absorbance measured for the positive control (both 
values are corrected with the background). Therefore, the resulted % haemolysis values are 
independent from the exact absorbance values. However, better results can be obtained if we 
measure at the maximum wavelength of the released haemoglobin. We found that the highest 
values can be measured if we monitor the absorbance at 414 nm or 405 nm (TABLE 3).  
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TABLE 3. Absorbance of the released haemoglobin at different wavelength 
Wavelength Absorbance a ± Sd a 
340 nm 2.034 0.001 
405 nm 4.456 0.016 
414 nm 4.576 0.120 
450 nm 1.190 0.018 
492 nm 0.440 0.003 
540 nm 1.047 0.006 
Peptide treated erythrocytes were centrifuged and the supernatants were 
transferred to a flat-bottom microtiter plate. The absorbance was measured at 
various wavelengths using an ELISA plate reader.  
a Means and standard deviations of two measurements. 
   
3.2.2. Concentration of Red Blood Cells, Presence of BSA, Anticoagulant and Counter Ion 
The percentage or cell number of RBC used in haemolytic assays differs in a wide concentration 
range. Therefore, to clarify the effect of RBC content, haemolysis of CM15 peptide was studied 
at 4%, 1%, 0.25% or 0.0625% RBC concentration. No difference was measured (P = 0.2862) 
for 4%, 1%, 0.25%, while at 0.0625% RBC concentration significantly lower HC50 value was 
measured (P = 0.0004) (FIGURE 3A) 
 
Peptide and protein solutions are prone to loose activity as a result of aggregation, loss of 
original structure integrity and/or binding to the storage vessel. Therefore, it is widely 
recommended to dilute the samples in a buffer containing a stabilizer. The addition of bovine 
serum albumin (BSA) in a concentration of 1-10 mg/ml (0.1-1%) is a popular way to protect 
against such degradation and loss. To study the effect of BSA addition, CM15 peptide was 
diluted in a presence of 5 mg/mL (0.5%) BSA and the haemolytic activity was tested. The 
results showed that the addition of BSA has no significant effect on the haemolytic activity of 
CM15 peptide (P = 0.1018) (FIGURE 3B). 
 
Although, published methods for analysis of haemolytic activity of cationic peptides mentioned 
different anticoagulant containing vacuum tubes for cupping, no systematic study was 
evaluated on the effect of anticoagulants. Therefore, most frequently used anticoagulant 
containing vacuum tubes were used to compare the effect of citrate, heparin and EDTA on the 
haemolytic activity of CM15 peptide. The results clearly showed that lysis of the red blood cells 
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by CM15 cationic peptide was independent of the used anticoagulant (P = 0.1210) (FIGURE 
3C). 
 
In the case of lysine and arginine rich peptides, the high amount of TFA could alter the 
biological activity. Therefore, excess TFA and trifluoroacetate counter-ion was removed and 
changed to acetate counter-ion and the haemolytic activity of trifluoroacetate and acetate 
counter-ion containing CM15 peptide was assayed. No marked effect of counter-ion identity 
could be observed in case of CM15 peptide treated RBC (P = 0.4106) (FIGURE 3D).  
  
FIGURE 3. Effect of erythrocyte concentration (A) presence of bovine serum albumin (B), 
identity of anticoagulant (C) and counter-ion (D) on the haemolytic activity of CM15 peptide. 
Human RBCs were treated with CM15 peptide using different test conditions and the haemolysis 
was determined by reading the absorbance of the supernatant at λ= 414 nm. Haemoglobin release 
of 4%, 1%, 0.25% v/v RBCs evoked by the CM15 peptide showed no significant difference, while 
at 0.0625% RBC concentration significantly lower HC50 value was measured  (A).  The addition of 
BSA to the test solution of CM15 does not alter its haemolytic activity (B). No significant differences 
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in the resulted HC50 values were detected after using three different anticoagulants (C). Counter-ion 
replacement has no significant effect on the haemolytic activity of CM15 peptide. 
 
 
3.3. Cytotoxicity of Cationic Peptides 
Cytotoxicity of cationic peptides was studied on freshly prepared human PBMC in RPMI media 
(incubation time was 4 hrs) using MTT test. PBMC are isolated human cells which can be used 
to study general toxicity of a compound. The following order of cytotoxicity was found: (i) 
Melittin, Transportan, CM15 and Dhvar4 peptides have IC50 value lower than 50 μM; (ii) 
modest cytotoxicity (50 – 300 μM) was measured for GranF2, Magainin and Penetratin; (iii) 
Tat(47-57), Buforin II, Crot(1-9,38-42) and OT20 peptides were not cytotoxic up to 300 M 
(TABLE 4).  
 
When measuring the haemolytic activity of the peptides employing the same experimental 
conditions as for the cytotoxic assay (RPMI media, 4 hrs of incubation), almost the same order 
of activity was found, namely the highest HC50 values were measured for Melittin, Transportan, 
CM15, and Transportan. Dhvar4 and GranF2 peptides were found to be cytotoxic to PBMC 
cells but not for red blood cells (HC50 > 300 μM).  
 
TABLE 4. Cytotoxic, haemolytic  and antibacterial effect of cationic oligopeptides 
peptide IC50 a 
(M) 
HC50 b 
(M) 
MIC c 
(M) 
HC50 d 
(M) 
Selectivity 
index e 
MTB MIC f 
(M) 
Tat(47-57) >300 >300 300 >300 1 >300 
Penetratin 136±25.6 >300 1.2 >300 250 >300 
Transportan 8.49±1.39 38.0±3.79 1.2 25.2±3.29 21 80 
Magainin 132±23.8 >300 33 >300 9 >300 
Buforin II (5-21) >300 >300 >300 >300 1 >300 
GranF2 80.1±18.5 >300 100 269±7.11 3 >300 
Dhvar4 38.6±5.76 >300 3.7 >300 81 >300 
Crot(1-9,38-42) >300 >300 >300 >300 1 >300 
CM15 12.9±2.51 18.9±1.71 1.2 13.9±0.456 12 >300 
Melittin 0.941±0.237 0.339±0.0854 1.2 0.681±0.0542 0.6 >300 
OT20 >300 >300 >300 >300 1 >300 
a Mean IC50 ± standard deviation. Cytotoxicity of peptides on human PBMC measured in RPMI media (4 hrs 
incubation time).  
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b Mean HC50 ± standard deviation. HC50 is a concentration at which 50% haemolysis of human RBCs occurs in 
RPMI (without phenol red) media (4 hrs incubation time).  
c Minimal inhibitory concentration on Streptococcus pneumoniae strain determined in Bouillon broth (24 hrs of 
incubation).  
d Mean HC50 ± standard deviation determined in Bouillon broth with 24 hrs of incubation. 
e Selectivity index was calculated from HC50/MIC (both measured in Bouillon broth).  
f Minimal inhibitory concentration on Mycobacterium tuberculosis H37Rv strain determined in Sula media.  
For samples, where MIC, IC50 or HC50 was higher than 300 M, a value of 300 M was assigned. 
 
To estimate the cell-type dependence of cationic peptides four different human cells and cell 
lines were used. HepG2 human hepatocytes and SH-SY5Y human neuroblastoma cells are 
frequently used as hepatotoxicity and neurotoxicity model. MonoMac6 human monocytic cell 
line is a macrophage model which is suitable to bear intracellular bacteria. Cells were treated 
with Transportan at various peptide concentrations and the cytotoxicity was determined by 
MTT assay. Mean IC50 values showed significant difference (P < 0.05) however, all IC50 were 
in the same concentration range: 4.70±1.02 M (MonoMac6), 6.78±0.488 M (HepG2), 
8.28±0.573 M (SH-SY5Y), 9.81±0.473 M (PBMC) (FIGURE 4).  
 
 
FIGURE 4. Cell-type dependence in the cytotoxicity assay. Freshly isolated PBMC, MonoMac6 
human monocytes, HepG2 human hepatocytes and SH-SY5Y human neuroblastoma cells were 
treated with the peptide for 4 hrs at various concentrations and the cytotoxicity was determined by 
MTT assay. Comparing the IC50 values in one-way ANOVA test, significant difference was 
calculated however, the resulted IC50 values were at the same concentration range (between 4.70 
μM and 9.81 μM). 
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MonoMac6, which are adherent cells, were chosen to visualize the changes in the cell 
morphology caused by cationic peptides (FIGURE 5). Microscopic images of the peptide 
treated cells were captured using an Olympus CKX41 microscope. After treatment with Buforin 
II (5-21), Crot(1-9,38-42) and OT20 peptides, intact MonoMac6 cells were observed. Melittin, 
Transportan, CM15, Dhvar4 and GranF2 peptides caused severe damage on the cell membrane 
and provoked dramatic changes in the cell morphology. Penetratin, Magainin and Tat(47-57) 
peptides effected the cell membrane integrity just at the highest (100 M) concentration. These 
microscopic observations are in accordance with the result of the MTT assay. 
FIGURE 5. Microscopic images of cationic peptide treated MonoMac6 cells. Cells were incubated 
with the peptides for 4 hrs at 1, 10 and 100 M final concentration. Dramatic changes in the cell 
morphology were captured in the case of Melittin, Transportan, Dhvar4, CM15, and GranF2 
peptides, which results are in accordance with the MTT assay.  
 
3.4. Internalisation of Cationic Peptides 
Cellular uptake of MonoMac6 human monocytic cells was measured by flow cytometry. For 
that purpose, peptides were labelled with 5(6)-carboxyfluorescein (Cf) and measured at 20, 10 
and 5 µM final concentrations (FIGURE 6). Based on the internalisation ability, three groups 
of peptides were created: (i) superior penetration was defined for peptides where the percentage 
of FITC positive cells was higher than 80% at 5 µM concentration – Penetratin, Transportan, 
Dhvar4 and Melittin; (ii) good penetration for peptides where the percentage of FITC positive 
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cells was higher than 50% at 10 µM concentration – Tat, GranF2, CM15 and Buforin II; and 
(iii) modest penetration where the percentage of FITC positive cells was higher than 50% at 20 
µM concentration – Crot(1-9,38-42), Magainin II and OT20. It is important to note, that 
peptides with superior penetration shows the highest cytotoxicity, especially Melittin, 
Transportan and Dhvar4. However, Penetratin, Tat and Buforin II peptides bear good 
internalisation property but low cytotoxicity.  
 
FIGURE 6. Internalisation of cationic peptides. Cellular uptake of MonoMac6 cells were 
measured by flow cytometry using 5(6)-carboxyfluorescein (Cf)-labelled peptides at 5, 10 and 20 
μM concentration. The penetration ability was ranked according to the resulted percentage of FITC 
positive cells. Superior penetration: Penetratin, Transportan, Dhvar4 and Melittin; good 
penetrations: Tat, GranF2, CM15 and Buforin II; modest penetration: Crot(1-9,38-42), Magainin II 
and OT20. 
 
3.5. Antibacterial Activity against S. pneumonia. 
Antimicrobial efficacy of cationic peptides was measured against Streptococcus pneumoniae, 
a Gram-positive bacterium which is one of the most significant human pathogen (TABLE 4). 
Buforin II, Crot(1-9,38-42), Tat and OT20 control peptide were not effective against S. 
pneumonia. Magainin and GranF2 showed modest activity; CM15 and Dhvar4 peptides had 
potent antibacterial activity (less than 4 M) just as Melittin. Interestingly, Penetratin and 
Transportan, which are classified as cell penetrating peptides, showed relevant antibacterial 
activity against Streptococcus pneumoniae. In the case of Penetratin, these findings are in 
accordance with a previous data, which suggested that the membrane induced –helical 
structure makes this peptide similar in activity to AMPs (Magzoub et al. 2002; Zhu and Shin 
2009).  
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3.6. Transportan Is Effective against M. tuberculosis 
Antitubercular effect of all peptides was tested also on M. tuberculosis H37Rv strain. M. 
tuberculosis, the causative agent of tuberculosis, can survive in the host phagocytes for years 
or even decades and it is estimated that more than one-third of the world’s population are 
infected with these pathogen (Lienhardt et al. 2012). Our results demonstrated that none of the 
peptides were effective against M. tuberculosis up to 300 μM concentration, except 
Transportan. The MIC of Transportan peptide was 80 M. No published data were found 
recently on the antitubercular effect of Transportan.  
 
3.7. In Vitro Selectivity of Cationic Peptides 
We found, that the haemolytic activity of the tested peptides is significantly lower in PBS than 
in RPMI or in Bouillon broth. Therefore, selectivity indices (given in TABLE 4) were 
calculated from the results of experiments using the same buffer and incubation time. Based on 
the comparison of antitubercular effect and haemolytic activity, most selective peptides (where 
the selectivity indices were higher than 20) were Penetratin, Dhvar4 and Transportan. Among 
these peptides, Penetratin showed the best selectivity, because the MIC value of Penetratin was 
250 times lower than its HC50 value. Modest selectivity was found for Magainin II, GranF2 and 
CM15 peptides. Up to the highest concentration (300 M) no antibacterial and haemolytic 
activities were observed for Buforin II, Crot(1-9,38-42), Tat and OT20 peptides (TABLE 4). In 
the case of the positive control peptide Melittin, the MIC value was higher than the HC50 value.  
 
4. CONCLUSION 
 
Here we report the comparative analysis of cationic oligopeptides to identify potent 
antibacterial carriers for drug delivery. Peptide synthesis and purification was followed by 
accurate characterization of the product (molecular mass, retention time, peptide content). 
Haemolytic activity and cytotoxicity on isolated human blood cells and different cell lines have 
been systematically studied and compared to their penetrating ability and antibacterial activity 
against Streptococcus pneumoniae (pneumococcus) and Mycobacterium tuberculosis. We also 
clarified the role of the used media, incubation time, RBC concentration, addition of BSA, type 
of anticoagulant and counter-ion on the haemolytic activity of the peptides. We found, that the 
lytic activity of cationic peptides strongly depends on the used incubation media, which 
observation is in accordance with the results of the circular dichroism measurement. Therefore, 
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it is uncertain whether the results of haemolytic assays, that are conducted in high salt buffers 
such as Tris od PBS, can be compared properly with the results of antibacterial assays, that are 
conducted in low ionic strength buffers or broths. Because of this observation, the same 
incubation media was applied both for the antibacterial assay and the haemolytic assay. We 
also found that the haemolytic activity of cationic peptides was almost independent from the 
other conditions like incubation time and type of anticoagulant. For a proper haemolytic assay, 
performed on human erythrocytes, at least 0.25% v/v RBC concentration is required, which is 
equal to approximately 1 - 1.25 × 107 cells / mL (counting with the reference range of RBC of 
a male or female blood). When measuring the cytotoxicity of cationic peptides on different 
human cells and cell lines, almost the same order of activity was found than in the haemolytic 
assay.   
 
As a summary of the performed assays we can conclude the following: (i) eight peptides showed 
superior or good penetration of which Tat, Penetratin, Dhvar4 and Buforin peptides have low 
haemolytic activity. Therefore, these peptides can be considered as good carriers for different 
drug molecules without causing severe damage on human cells. (ii) Transportan was found to 
be effective against M. tuberculosis H37Rv bacteria. However, Transportan was cytotoxic at 
this concentration range. (iii) Dhvar4 peptide showed superior antibacterial effect and 
penetration ability although, this peptide was cytotoxic to human PBMC but not to human 
erythrocytes. (iv) Penetratin was identified as promising antibacterial drug carrier with potent 
antibacterial effect (MIC lower than 1.2 M on pneumococcus) and superior penetration ability 
with low in vitro toxicity on human cells. Conjugation of an antibacterial drug to an antibacterial 
peptide is proposed to intensify the efficacy by multiple mode of action: including bacterial cell 
lysis, inhibiting bacterial enzymes, interacting directly with the cytoplasmic membrane and 
inhibiting intracellular targets. In addition, the consequence of the multiple mechanism of action 
is the low potential to induce microbial resistance. Therefore, Penetratin and its analogues with 
remarkable antibacterial activity and high selectivity will be further investigated as drug 
delivery systems for antibacterial agents.  
 
  
 27 
COMPLIANCE WITH ETHICAL STANDARDS 
 
Conflict of Interest: The authors declare that they have no conflict of interest. 
Funding: This study was funded by the Hungarian Research Fund (115431 and 104275) and 
by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences.  
Informed consent: The authors confirm that this work is new and original and not under 
consideration elsewhere. Our institute, the MTA-ELTE Research Group of Peptide Chemistry, 
Hungarian Academy of Sciences, and all authors have agreed to the submission of this 
manuscript. 
Research involving human participants and/or animals: This article does not contain any 
studies with human participants or animals performed by any of the authors. 
 
 
 
 
  
 28 
REFERENCES 
Amon MA, Ali M, Bender V, Hall K, Aguilar MI, Aldrich-Wright J, Manolios N (2008) Kinetic 
and conformational properties of a novel T-cell antigen receptor transmembrane peptide 
in model membranes. J Pept Sci 14:714-724. doi:10.1002/psc.987 
Andreu D, Carreno C, Linde C, Boman HG, Andersson M (1999) Identification of an anti-
mycobacterial domain in NK-lysin and granulysin. Biochem J 344:845-849. 
doi:10.1042/bj3440845  
Andreu D, Ubach J, Boman A, Wahlin B, Wade D, Merrifield RB, Boman HG (1992) 
Shortened cecropin A-melittin hybrids. Significant size reduction retains potent 
antibiotic activity. FEBS Lett 296:190-194. doi:10.1016/0014-5793(92)80377-S 
Bai KB, Lang O, Orban E, Szabo R, Kohidai L, Hudecz F, Mezo G (2008) Design, synthesis, 
and in vitro activity of novel drug delivery systems containing tuftsin derivatives and 
methotrexate. Bioconjug Chem 19:2260-2269. doi:10.1021/bc800115w 
Baranyai Z et al. (2015) Combating highly resistant emerging pathogen Mycobacterium 
abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and 
carbamates. Eur J Med Chem 101:692-704. doi:10.1016/j.ejmech.2015.07.001 
Brown ED, Wright GD (2016) Antibacterial drug discovery in the resistance era. Nature 
529:336-343. doi:10.1038/nature17042 
Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS (2005) Rational design of 
alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic 
index. J Biol Chem 280:12316-12329. doi:10.1074/jbc.M413406200 
Chongsiriwatana NP et al. (2008) Peptoids that mimic the structure, function, and mechanism 
of helical antimicrobial peptides. PNAS 105:2794-2799. doi:10.1073/pnas.0708254105 
Dathe M, Nikolenko H, Meyer J, Beyermann M, Bienert M (2001) Optimization of the 
antimicrobial activity of magainin peptides by modification of charge. Febs Lett 
501:146-150. doi:10.1016/S0014-5793(01)02648-5 
 29 
Dathe M et al. (1996) Peptide helicity and membrane surface charge modulate the balance of 
electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. 
Biochemistry 35:12612-12622. doi:10.1021/bi960835f 
Davanco MG et al. (2014) Evaluation of Antimalarial Activity and Toxicity of a New 
Primaquine Prodrug. Plos One 9 doi:10.1371/journal.pone.0105217 
Dennison SR, Phoenix DA (2014) Susceptibility of sheep, human, and pig erythrocytes to 
haemolysis by the antimicrobial peptide Modelin 5. Eur Biophys J 43:423-432. 
doi:10.1007/s00249-014-0974-9 
Derossi D, Joliot AH, Chassaing G, Prochiantz A (1994) The third helix of the Antennapedia 
homeodomain translocates through biological membranes. J Biol Chem 269:10444-
10450. doi:PMID:8144628  
El-Andaloussi S, Holm T, Langel U (2005) Cell-penetrating peptides: mechanisms and 
applications. Curr Pharm Des 11:3597-3611. doi:10.2174/138161205774580796 
Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized 
human immunodeficiency virus tat trans-activator protein. Cell 55:1179-1188. 
doi:10.1016/0092-8674(88)90262-0 
Habermann E (1972) Bee and wasp venoms. Science 177:314-322. 
doi:10.1126/science.177.4046.314  
Helmerhorst EJ, Reijnders IM, van't Hof W, Veerman ECI, Amerongen AVN (1999) A critical 
comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. 
Febs Letters 449:105-110. doi:10.1016/S0014-5793(99)00411-1 
Helmerhorst EJ, Van't Hof W, Veerman EC, Simoons-Smit I, Amerongen AVN (1997) 
Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochemistry 
326:39-45. doi:WOS:A1997XR05800005 
Herbel V, Wink M (2016) Mode of action and membrane specificity of the antimicrobial 
peptide snakin-2. Peerj 4 doi:10.7717/peerj.1987 
 30 
Hollmann A et al. (2016) Role of amphipathicity and hydrophobicity in the balance between 
hemolysis and peptide-membrane interactions of three related antimicrobial peptides. 
Colloids Surf B Biointerfaces 141:528-536. doi:10.1016/j.colsurfb.2016.02.003 
Hopp TP, Woods KR (1981) Prediction of protein antigenic determinants from amino acid 
sequences. PNAS 78:3824-3828. doi:PMID: 6167991 
Horvati K et al. (2012) Enhanced Cellular Uptake of a New, in Silico Identified Antitubercular 
Candidate by Peptide Conjugation. Bioconjug Chem doi:10.1021/bc200221t 
Horvati K et al. (2015) Antimycobacterial activity of peptide conjugate of pyridopyrimidine 
derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models. 
Tuberculosis 95:S207-S211. doi:10.1016/j.tube.2015.02.026 
Hudecz F, Banoczi Z, Csik G (2005) Medium-sized peptides as built in carriers for biologically 
active compounds. Med Res Rev 25:679-736. doi:10.1002/med.20034 
Kaushik NK, Sharma J, Sahal D (2012) Anti-plasmodial action of de novo-designed, cationic, 
lysine-branched, amphipathic, helical peptides. Malaria J 11:256. doi:10.1186/1475-
2875-11-256 
Kobayashi S, Takeshima K, Park CB, Kim SC, Matsuzaki K (2000) Interactions of the novel 
antimicrobial peptide buforin 2 with lipid bilayers: Proline as a translocation promoting 
factor. Biochemistry 39:8648-8654. doi:10.1021/bi0004549 
Langel U, Pooga M, Kairane C, Zilmer M, Bartfai T (1996) A galanin-mastoparan chimeric 
peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain. Regul 
Pept 62:47-52. doi:10.1016/0167-0115(96)00002-X 
Lee J, Lee DG (2008) Structure-antimicrobial activity relationship between pleurocidin and its 
enantiomer. Exp Mol Med 40:370-376. doi:10.3858/emm.2008.40.4.370 
Li Q et al. (2005) Hemolysis of erythrocytes by granulysin-derived peptides but not by 
granulysin. Antimicrob Agents Ch 49:388-397. doi:10.1128/AAC.49.1.388-397.2005 
Lienhardt C, Glaziou P, Uplekar M, Lonnroth K, Getahun H, Raviglione M (2012) Global 
tuberculosis control: lessons learnt and future prospects. Nat Rev Microbiol 10:407-416. 
doi:10.1038/nrmicro2797 
 31 
Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanism of cellular 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 
69:581-593. doi:10.1046/j.1471-4159.1997.69020581.x 
Magzoub M, Eriksson LE, Graslund A (2002) Conformational states of the cell-penetrating 
peptide penetratin when interacting with phospholipid vesicles: effects of surface charge 
and peptide concentration. Biochim Biophys Acta 1563:53-63. doi:10.1016/S0005-
2736(02)00373-5 
Maher S, McClean S (2006) Investigation of the cytotoxicity of eukaryotic and prokaryotic 
antimicrobial peptides in intestinal epithelial cells in vitro. Biochem Pharmacol 
71:1289-1298. doi:10.1016/j.bcp.2006.01.012 
Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides for therapeutic use: 
obstacles and realistic outlook. Curr Opin Pharmacol 6:468-472. 
doi:10.1016/j.coph.2006.04.006 
Mezo G et al. (2004) Synthesis, conformation, and immunoreactivity of new carrier molecules 
based on repeated tuftsin-like sequence. Biopolymers 73:645-656. 
doi:10.1002/bip.20024 
Mojsoska B, Zuckermann RN, Jenssen H (2015) Structure-activity relationship study of novel 
peptoids that mimic the structure of antimicrobial peptides. Antimicrob Agents 
Chemother 59:4112-4120. doi:10.1128/AAC.00237-15 
Morris MC, Deshayes S, Heitz F, Divita G (2008) Cell-penetrating peptides: from molecular 
mechanisms to therapeutics. Biol Cell 100:201-217. doi:10.1042/BC20070116 
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. doi:10.1016/0022-
1759(83)90303-4 
Park CB, Kim MS, Kim SC (1996) A novel antimicrobial peptide from Bufo bufo gargarizans. 
Biochem Biophys Res Commun 218:408-413. doi:10.1006/bbrc.1996.0071 
 32 
Pistolesi S, Pogni R, Feix JB (2007) Membrane insertion and bilayer perturbation by 
antimicrobial peptide CM15. Biophysical J 93:1651-1660. 
doi:10.1529/biophysj.107.104034 
Portlock SH, Clague MJ, Cherry RJ (1990) Leakage of internal markers from erythrocytes and 
lipid vesicles induced by melittin, gramicidin S and alamethicin: a comparative study. 
Biochim Biophys Acta 1030:1-10. doi:10.1016/0005-2736(90)90231-C 
Radis-Baptista G, de la Torre BG, Andreu D (2008) A novel cell-penetrating peptide sequence 
derived by structural minimization of a snake toxin exhibits preferential nucleolar 
localization. J Med Chem 51:7041-7044. doi:10.1021/jm8009475 
Raghuraman H, Chattopadhyay A (2006) Effect of ionic strength on folding and aggregation of 
the hemolytic peptide melittin in solution. Biopolymers 83:111-121. 
doi:10.1002/bip.20536 
Raghuraman H, Ganguly S, Chattopadhyay A (2006) Effect of ionic strength on the 
organization and dynamics of membrane-bound melittin. Biophys Chem 124:115-124. 
doi:10.1016/j.bpc.2006.06.011 
Reddy KV, Yedery RD, Aranha C (2004) Antimicrobial peptides: premises and promises. Int J 
Antimicrob Agents 24:536-547. doi:10.1016/j.ijantimicag.2004.09.005 
Reed J, Reed TA (1997) A set of constructed type spectra for the practical estimation of peptide 
secondary structure from circular dichroism. Anal Biochem 254:36-40. 
doi:10.1006/abio.1997.2355 
Rogers RN, Yasuda SK (1959) Rapid microdetermination of Fluorine in organic compounds. 
Anal Chem 31:616-617. doi:10.1021/ac50164a049 
Roux S, Zekri E, Rousseau B, Paternostre M, Cintrat JC, Fay N (2008) Elimination and 
exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of 
different approaches. J Pept Sci 14:354-359. doi:10.1002/psc.951 
Saberwal G, Nagaraj R (1994) Cell-lytic and antibacterial peptides that act by perturbing the 
barrier function of membranes: facets of their conformational features, structure-
 33 
function correlations and membrane-perturbing abilities. Biochim Biophys Acta 
1197:109-131. doi:10.1016/0304-4157(94)90002-7 
Slater TF, Sawyer B, Straeuli U (1963) Studies on Succinate-Tetrazolium Reductase Systems. 
Iii. Points of Coupling of Four Different Tetrazolium Salts. Biochim Biophys Acta 
77:383-393. doi:10.1016/0006-3002(63)90513-4 
Song YM et al. (2005) Cell selectivity and mechanism of action of antimicrobial model peptides 
containing peptoid residues. Biochemistry 44:12094-12106. doi:10.1021/bi050765p 
Stenger S et al. (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. 
Science 282:121-125. doi:10.1126/science.282.5386.121  
Sula L (1963) Who Co-Operative Studies on a Simple Culture Technique for the Isolation of 
Mycobacteria. 1. Preparation, Lyophilization and Reconstitution of a Simple Semi-
Synthetic Concentrated Liquid Medium; Culture Technique; Growth Pattern of 
Different Mycobacteria. Bull World Health Organ 29:589-606. doi:PMCID: 
PMC2555071 
Sula L, Sundaresan TK (1963) Who Co-Operative Studies on a Simple Culture Technique for 
the Isolation of Mycobacteria. 2. Comparison of the Efficacy of Lyophilized Liquid 
Medium with That of Loewenstein-Jensen (L-J) Medium. Bull World Health Organ 
29:607-625. doi:PMCID: 2555071 
Toniolo C, Formaggio F, Woody RW (2012) Electronic Circular Dichroism of Peptides. In: 
Berova N, Polavarapu PL, Nakanishi K, Woody RW (eds) Comprehensive Chiroptical 
Spectroscopy: Applications in Stereochemical Analysis of Synthetic Compounds, 
Natural Products, and Biomolecules, vol 2. pp 499-544. doi:10.1002/9781118120392 
Vemuri S (2005) Comparison of assays for determination of peptide content for lyophilized 
thymalfasin. J Pept Res 65:433-439. doi:10.1111/j.1399-3011.2005.00225.x 
Vinsova J et al. (2006) Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-
butylbenzoxazoles. Bioorg Med Chem 14:5850-5865. doi:10.1016/j.bmc.2006.05.030 
Vives E, Schmidt J, Pelegrin A (2008) Cell-penetrating and cell-targeting peptides in drug 
delivery. Biochim Biophys Acta 1786:126-138. doi:10.1016/j.bbcan.2008.03.001 
 34 
Wu S et al. (2014) Genomic and functional characterization of three new venom peptides from 
the scorpion Heterometrus spinifer. Peptides 53:30-41. 
doi:10.1016/j.peptides.2013.12.012 
Yang QZ, Wang C, Lang L, Zhou Y, Wang H, Shang DJ (2013) Design of potent, non-toxic 
anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa. 
Arch Pharm Res 36:1302-1310. doi:10.1007/s12272-013-0112-8 
Yeaman MR, Yount NY (2003) Mechanisms of antimicrobial peptide action and resistance. 
Pharmacol Rev 55:27-55. doi:10.1124/pr.55.1.2 
Yeung AT, Gellatly SL, Hancock RE (2011) Multifunctional cationic host defence peptides and 
their clinical applications. Cell Mol Life Sci 68:2161-2176. doi:10.1007/s00018-011-
0710-x 
Zasloff M (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, 
characterization of two active forms, and partial cDNA sequence of a precursor. Proc 
Natl Acad Sci U S A 84:5449-5453. doi:10.1073/pnas.84.15.5449 
Zeitler B, Diaz AH, Dangel A, Thellmann M, Meyer H, Sattler M, Lindermayr C (2013) De-
Novo Design of Antimicrobial Peptides for Plant Protection. Plos One 8 
doi:10.1371/journal.pone.0071687 
Zhu WL, Shin SY (2009) Antimicrobial and cytolytic activities and plausible mode of 
bactericidal action of the cell penetrating peptide penetratin and its lys-linked two-
stranded peptide. Chem Biol Drug Des 73:209-215. doi:10.1111/j.1747-
0285.2008.00769.x 
 
 
 
